Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuronetics (STIM) Asset Writedowns and Impairment (2022 - 2025)

Historic Asset Writedowns and Impairment for Neuronetics (STIM) over the last 4 years, with Q3 2025 value amounting to $205000.0.

  • Neuronetics' Asset Writedowns and Impairment fell 7108.6% to $205000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year increase of 2506.42%. This contributed to the annual value of $4.0 million for FY2024, which is 10997.38% up from last year.
  • Neuronetics' Asset Writedowns and Impairment amounted to $205000.0 in Q3 2025, which was down 7108.6% from $172000.0 recorded in Q2 2025.
  • Over the past 5 years, Neuronetics' Asset Writedowns and Impairment peaked at $2.2 million during Q3 2023, and registered a low of -$596000.0 during Q2 2023.
  • For the 4-year period, Neuronetics' Asset Writedowns and Impairment averaged around $572727.3, with its median value being $330000.0 (2023).
  • In the last 5 years, Neuronetics' Asset Writedowns and Impairment surged by 21275.17% in 2024 and then tumbled by 9911.66% in 2025.
  • Neuronetics' Asset Writedowns and Impairment (Quarter) stood at $13000.0 in 2022, then surged by 16600.0% to $2.2 million in 2023, then dropped by 5.44% to $2.1 million in 2024, then plummeted by 90.01% to $205000.0 in 2025.
  • Its Asset Writedowns and Impairment stands at $205000.0 for Q3 2025, versus $172000.0 for Q2 2025 and $5000.0 for Q1 2025.